Chemical formula: C₂₄H₃₃NO₃ Molecular mass: 383.524 g/mol
In the absence of any relevant clinical data, the use of naftidrofuryl is not advisable during pregnancy.
In the absence of specific data concerning the excretion of the drug in human milk, naftidrofuryl should not be used by breast-feeding women.
As naftidrofuryl can cause dizziness patient should make sure they are not affected before driving or operating machinery.
According to information collected during clinical trials and spontaneous reports since marketing authorisation, the following undesirable effects may occur under treatment with Naftidrofuryl.
The following definitions apply to the frequency terminology used hereafter: very common ≥1/10, common ≥1/100, <1/10, uncommon ≥1/1,000, <1/100, rare ≥1/10,000, <1/1,000, very rare <1/10,000, frequency not known: cannot be estimated from the available data.
Uncommon: Diarrhoea, nausea, vomiting and epigastric pain.
Frequency not known: In some patients who took the medicinal product without liquid before going to bed, the capsule being stuck in the throat led to local oesophagitis.
Very rare: Calcium oxalate kidney stones.
Uncommon: Skin rash.
Rare: Liver damage.
Frequency not known: Hepatitis and hepatic failure.
Frequency not known: Dizziness, headache, agitation and sleep disorders.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
